Critical Pathways Using Platelet Testing to Potentially Optimize the Use of Oral Antiplatelet Therapy - 17/08/11
, Dalton S. McLean, MD b
Address for reprints: Christopher P. Cannon, MD, TIMI Study Group, Brigham and Women’s Hospital, 75 Francis Street, Boston, Massachusetts 02115.Résumé |
Although monitoring anticoagulation is standard practice, monitoring antiplatelet therapy has not yet widely been adopted as a means of assessing antithrombotic response. However, bedside devices have recently become available that facilitate more rapid assessment of antithrombotic response, allowing this information to be developed into a critical pathway. Three major opportunities exist for oral antiplatelet therapy: (1) optimizing the dose of aspirin for long-term therapy; (2) optimizing the dose of clopidogrel, especially in percutaneous coronary intervention, acutely and during long-term therapy; and (3) evaluating the level of platelet inhibition before coronary artery bypass grafting or other major surgery. Several critical pathways are proposed that may assist clinicians in trying to ensure adequate platelet inhibition in these important clinical situations.
Le texte complet de cet article est disponible en PDF.Plan
Vol 98 - N° 10S1
P. S33-S38 - novembre 2006 Retour au numéro
Article précédent
- Impact of Platelet Testing on Presurgical Screening and Implications for Cardiac and Noncardiac Surgical Procedures
- Arthur W. Bracey, Alina M. Grigore, Nancy A. Nussmeier
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?